Neurological Sciences

, Volume 26, Supplement 2, pp s162–s166

Naratriptan in the short-term prophylaxis of pure menstrual migraine

Authors

  • F. Moschiano
    • L. Mandic Hospital
  • G. Allais
    • Woman’s Headache Center, Dept. of Gynecology and ObstetricsUniversity of Turin
  • L. Grazzi
    • C. Besta National Neurological Institute
  • S. Usai
    • C. Besta National Neurological Institute
  • C. Benedetto
    • Woman’s Headache Center, Dept. of Gynecology and ObstetricsUniversity of Turin
  • D. D’Amico
    • C. Besta National Neurological Institute
  • M. Roncolato
    • GSK Italy Neuroscience Medical Department
    • C. Besta National Neurological Institute
ORAL COMMUNICATION

DOI: 10.1007/s10072-005-0435-4

Cite this article as:
Moschiano, F., Allais, G., Grazzi, L. et al. Neurol Sci (2005) 26: s162. doi:10.1007/s10072-005-0435-4

Abstract

Menstrual migraines are particularly difficult-totreat. Few studies on the use of triptans in short-term prophylaxis of menstrually related migraine have been recently conducted, but evidences of triptans’ efficacy in the specific case of pure menstrual migraine (PMM) are lacking.

The aim of this study is to explore the efficacy and tolerability of naratriptan as short-term prophylaxis of pure menstrual migraine (PMM) attacks. A multi-centre, open, non comparative, pilot six-month study was conducted in women, aged 18 years or older, with regular menstrual cycles and with a history of migraine without aura exclusively associated to the perimenstrual period. After an observation period of three months, patients took for three consecutive menstrual cycles oral naratriptan 1 mg twice daily, starting two days before the expected onset of menstruation and continuing for six days. Ninety-eight women with a history of PMM were screened for study participation, and 61 entered the study. Fifty-nine comprised the intent-to-treat population. The mean number of PMM attacks decreased from 3.5±1.4 in the 3-month observation period to 1.6±1.3 in the 3-month treatment with naratriptan. The pecentage of responders (subjects who recorded a decrease—equal or more than 50%—in the mean number of attacks) was 61.4%. A tendency towards a decrease in headache severity and in the presence of associated symptoms was observed during treatment. At least one adverse event during the treatment period was reported by 19 patients (31.1%). No serious adverse events occurred. Naratriptan may be an effective and safe treatment option in the short-prophylaxis of PMM.

Key words

Short-term prophylaxisEfficacyNaratriptanPure menstrual migraineSafety

Copyright information

© Springer-Verlag Italia 2005